MetaADEDB 2.0 @ LMMD
Clofazimine
(WDQPAMHFFCXSNU-UHFFFAOYSA-N)
Structure
SMILES
Clc1ccc(cc1)Nc1cc2nc3ccccc3n(c2cc1=NC(C)C)c1ccc(cc1)Cl
Type(s)
Approved; Investigational
ATC code(s)
J04BA01
Molecular Formula:
C27H22Cl2N4
Molecular Weight:
473.396
Log P:
7.6112
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
1
TPSA:
42.21
CAS Number(s):
2030-63-9
Synonym(s)
1.
Clofazimine
2.
B-663
3.
G-30,320
4.
Lamprene
5.
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine
6.
B 663
7.
B663
8.
G 30,320
9.
G30,320
External Link(s)
MeSHD002991
PubChem Compound2794
BindingDB50378783
50318909
ChEBI3749
CHEMBLCHEMBL1369407
CHEMBL1083384
CHEMBL1292
DrugBankDB00845
DrugCentral692
IUPHAR/BPS Guide to PHARMACOLOGY9184
KEGGcpd:C06915
dr:D00278
Therapeutic Target DatabaseD0S5UH
D07NPR
ZINC100037101
253916263
17953024
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal PainFAERS: 616295502CTD
US FAERS
2Weight decreasedFAERS: 5SIDER
US FAERS
3FatigueFAERS: 4SIDER
US FAERS
4HeadacheFAERS: 4SIDER
US FAERS
5VomitingFAERS: 4SIDER
US FAERS
6Long QT SyndromeFAERS: 3US FAERS
7Product use in unapproved indicationFAERS: 3US FAERS
8AlopeciaFAERS: 2US FAERS
9Aspartate Aminotransferase IncreasedFAERS: 2US FAERS
10AstheniaFAERS: 2SIDER
US FAERS
11Blood immunoglobulin G decreasedFAERS: 2US FAERS
12BronchiectasisFAERS: 2US FAERS
13Cardiac ArrestFAERS: 2US FAERS
14Chest PainFAERS: 2US FAERS
15Complement factor C3 increasedFAERS: 2US FAERS
16DeafnessFAERS: 2US FAERS
17DehydrationFAERS: 2US FAERS
18Drug toxicityFAERS: 2US FAERS
19Eosinophil percentage increasedFAERS: 2US FAERS
20EpistaxisFAERS: 2US FAERS
21HistiocytosisFAERS: 2US FAERS
22Lip swellingFAERS: 2US FAERS
23NauseaFAERS: 2
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
24Night sweatsFAERS: 2US FAERS
25Oral fungal infectionFAERS: 2US FAERS
26PneumoniaFAERS: 2US FAERS
27Productive CoughFAERS: 2US FAERS
28Pulmonary HypertensionFAERS: 2US FAERS
29Respiratory FailureFAERS: 2US FAERS
30Rheumatoid FactorFAERS: 2US FAERS
31Septic ShockFAERS: 2US FAERS
32SynovitisFAERS: 2US FAERS
33UrticariaFAERS: 2US FAERS
34Visual ImpairmentFAERS: 2SIDER
US FAERS
35Abdominal discomfortFAERS: 1US FAERS
36Abdominal tendernessFAERS: 1US FAERS
37AbscessFAERS: 1US FAERS
38Accidental drug intake by childFAERS: 1US FAERS
39Accidental exposureFAERS: 1US FAERS
40Acute kidney injuryFAERS: 1US FAERS
41Alanine Aminotransferase IncreasedFAERS: 1US FAERS
42AngioedemaFAERS: 1US FAERS
43ArthralgiaFAERS: 1US FAERS
44Atrial FibrillationFAERS: 1US FAERS
45Atrial FlutterFAERS: 1US FAERS
46Blood alkaline phosphatase increasedFAERS: 1US FAERS
47BronchitisFAERS: 1US FAERS
48Cerebral calcificationFAERS: 1US FAERS
49Concomitant disease progressionFAERS: 1US FAERS
50Critical IllnessFAERS: 1US FAERS
51Crystal deposit intestineFAERS: 1US FAERS
52Deposit eyeFAERS: 1US FAERS
53Disease recurrenceFAERS: 1US FAERS
54DizzinessFAERS: 1SIDER
US FAERS
55Drug dispensing errorFAERS: 1US FAERS
56Dry skinFAERS: 1US FAERS
57DuodenitisFAERS: 1US FAERS
58DyspepsiaFAERS: 1US FAERS
59Ejection Fraction DecreasedFAERS: 1US FAERS
60EmpyemaFAERS: 1US FAERS
61Essential HypertensionFAERS: 1US FAERS
62Facial wastingFAERS: 1US FAERS
63Failure to ThriveFAERS: 1US FAERS
64GangreneFAERS: 1US FAERS
65GastroenteritisFAERS: 1US FAERS
66General physical health deteriorationFAERS: 1US FAERS
67HemiplegiaFAERS: 1US FAERS
68HypotensionFAERS: 1US FAERS
69IleusFAERS: 1US FAERS
70Implantable defibrillator insertionFAERS: 1US FAERS
71Incorrect dose administeredFAERS: 1US FAERS
72InfectionFAERS: 1US FAERS
73Intestinal ObstructionFAERS: 1SIDER
US FAERS
74IntubationFAERS: 1US FAERS
75Joint swellingFAERS: 1US FAERS
76LethargyFAERS: 1US FAERS
77LeukocytosisFAERS: 1US FAERS
78Low density lipoprotein increasedFAERS: 1US FAERS
79MalabsorptionFAERS: 1US FAERS
80MalnutritionFAERS: 1US FAERS
81Medication ErrorFAERS: 1US FAERS
82Melkersson-Rosenthal SyndromeFAERS: 1US FAERS
83MeningitisFAERS: 1US FAERS
84Metabolic acidosisFAERS: 1US FAERS
85Myocardial fibrosisFAERS: 1US FAERS
86Neck PainFAERS: 1US FAERS
87NeuritisFAERS: 1US FAERS
88Optic NeuropathyFAERS: 1US FAERS
89OverdoseFAERS: 1US FAERS
90PainFAERS: 1US FAERS
91PallorFAERS: 1US FAERS
92Peripheral swellingFAERS: 1US FAERS
93PeritonitisFAERS: 1US FAERS
94Product depositFAERS: 1US FAERS
95Product use issueFAERS: 1US FAERS
96PruritusFAERS: 1SIDER
US FAERS
97Pulmonary EmbolismFAERS: 1US FAERS
98Pyoderma GangrenosumFAERS: 17387877CTD
US FAERS
99RetchingFAERS: 1US FAERS
100ReticulocytosisFAERS: 1US FAERS
101SciaticaFAERS: 1US FAERS
102Scleral pigmentationFAERS: 1US FAERS
103SepsisFAERS: 1US FAERS
104ShockFAERS: 1US FAERS
105SinusitisFAERS: 1US FAERS
106Suicide attemptFAERS: 1US FAERS
107Therapy changeFAERS: 1US FAERS
108TremorFAERS: 1US FAERS
109Troponin increasedFAERS: 1US FAERS
110Type 2 lepra reactionFAERS: 1US FAERS
111Vascular encephalopathyFAERS: 1US FAERS
112Venous InsufficiencyFAERS: 1US FAERS
113WheezingFAERS: 1US FAERS
114Wrong technique in product usage processFAERS: 1US FAERS
115jaundiceFAERS: 1SIDER
US FAERS
116Agranulocytosis19274991
20140364
CTD
117Anemia, Hemolytic19274991
20140364
CTD
118AnorexiaSIDER
119Bladder painSIDER
120Bone painSIDER
121Cardiomyopathies29258954CTD
122CheilosisSIDER
123Completed SuicideSIDER
124ConstipationSIDER
125Corneal pigmentationSIDER
126CystitisSIDER
127Dermatitis acneiformCanada Vigilance: 1Canada Vigilance
SIDER
128DermatitisSIDER
129Diarrhea16295502CTD
130DrowsinessSIDER
131EmbolismSIDER
132EnteritisSIDER
133EosinophiliaSIDER
134Epigastric painSIDER
135HepatitisSIDER
136HepatomegalySIDER
137HyperkinesiaCanada Vigilance: 1Canada Vigilance
138Hypokalemia16295502CTD
139Leprosy, Lepromatous16038251
16638414
CTD
140Leprosy, Multibacillary20140364CTD
141Leprosy6260900
16015260
CTD
142LymphadenopathySIDER
143MyalgiaCanada Vigilance: 2Canada Vigilance
144NeuralgiaSIDER
145PhototoxicitySIDER
146Restless Legs SyndromeCanada Vigilance: 1Canada Vigilance
147Retinal pigmentationCanada Vigilance: 1Canada Vigilance
148SomnolenceSIDER
149Splenic Infarction7387877CTD
SIDER
150SuicideSIDER
151Taste DisordersSIDER
152ThromboembolismSIDER
153Vascular painSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.